| Assessment Status | Rapid review complete |
| HTA ID | 19047 |
| Drug | Upadacitinib |
| Brand | Rinvoq® |
| Indication | For the treatment of moderate-to-severe active rheumatoid arthritis in adult patients who have responded inadequately to, or who are intolerant to one or more disease-modifying anti-rheumatic drugs. Upadacitinib may be used as monotherapy or in combination with methotrexate. |
| Assessment Process | |
| Rapid review commissioned | 21/10/2019 |
| Rapid review completed | 10/12/2019 |
| Rapid review outcome | A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of upadacitinib (Rinvoq®) compared with the current standard of care, on the basis of the proposed price relative to currently available therapies. |
The HSE has approved reimbursement following confidential price negotiations February 2021.
